Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Perrottet, Nancy ^a   Manuel, Oriol ^a   Lamoth, Frédéric ^a   Venetz, Jean Pierre ^a   Sahli, Roland ^a   Decosterd, Laurent A ^a   Buclin, Thierry ^a   Pascual, Manuel ^a   Meylan, Pascal ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; VIRUS DNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LEUKOPENIA; LIVER GRAFT; MALE; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIRUS LOAD; AGED; ALLOTRANSPLANTATION; BLOOD; MIDDLE AGED; ORGAN TRANSPLANTATION; PROSPECTIVE STUDY;

AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 76749084808     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-2     Document Type: Article

References (18)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007, 357:2601-2614. 10.1056/NEJMra064928, 18094380.
2. Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Barbara M, Bromberg JS. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003, 3:731-735. 10.1034/j.1600-6143.2003.00140.x, 12780565.
3. Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Müller LC. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006, 81:1415-1420. 10.1097/01.tp.0000209439.27719.ed, 16732179.
4. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, . Valganciclovir Solid Organ Transplant Study Group Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4:611-620. 10.1111/j.1600-6143.2004.00382.x, 15023154, Valganciclovir Solid Organ Transplant Study Group.
5. Åsberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A, . VICTOR Study Group Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7:2106-2113. 10.1111/j.1600-6143.2007.01910.x, 17640310, VICTOR Study Group.
6. Perrottet N, Csajka C, Pascual M, Manuel O, Lamoth F, Meylan P, Aubert JD, Venetz JP, Soccal P, Decosterd LA, Biollaz J, Buclin T. Population pharmacokinetics of valganciclovir in solid organ transplant recipients. Antimicrob Agents Chemother 2009, 7:3017-3023.
7. Humar A, Michaels M, . AST ID Working Group on Infectious Disease Monitoring American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006, 6:262-274. 10.1111/j.1600-6143.2005.01207.x, 16426310, AST ID Working Group on Infectious Disease Monitoring.
8. Perrottet N, Beguin A, Meylan P, Pascual M, Manuel O, Buclin T, Biollaz J, Decosterd LA. Determination of aciclovir and ganciclovir in human plasma by liquid chromatography - spectrofluorimetric detection and stability studies in blood samples. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 852:420-429. 10.1016/j.jchromb.2007.01.045, 17303480.
9. Muheim C, Vogel G, Seydoux C, Gillet M, Mosimann F, Von Segesser L, Sahli R, Estrade C, Van Melle G, Meylan PR. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation 2002, 74:226-236. 10.1097/00007890-200207270-00014, 12151736.
10. Castor J, Cook L, Corey L, Jerome KR. Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J Clin Microbiol 2007, 45:2681-2683. 10.1128/JCM.00526-07, 1951258, 17537934.
11. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999, 12:286-297. 88918, 10194460.
12. Mattes FM, Hainsworth EG, Hassan-Walker AF, Burroughs AK, Sweny P, Griffiths PD, Emery VC. Kinetics of cytomegalovirus load decrease in solid organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005, 191:89-92. 10.1086/425905, 15593008.
13. Humar A, Siegal D, Moussa G, Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005, 192:1154-1157. 10.1086/444398, 16136456.
14. Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009, 48:399-418. 10.2165/00003088-200948060-00006, 19650679.
15. Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, Pellegrini C, Meloni F, Rampino T. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006, 6:2356-2364. 10.1111/j.1600-6143.2006.01488.x, 16889599.
16. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naïve and experience immnunocompromised hosts. J Infec Dis 2002, 185:1723-1728.
17. Manuel O, Pang X, Preiksaitis JK, Emery VC, Kumar D, Asberg A, Hartmann A, Pescovitz MD, Bignamini AA, Rollag H, Jardine AG, Humar A. A Prospective Study of Viral Genetic Polymorphisms in CMV Glycoprotein B and their Association with Clinical and Virologic Outcomes in Patients with CMV Disease. Am J Transplant 2008, 8(Suppl 2):184.
18. Mañez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, Dummer S, Ho M. Post-transplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus. J Infect Dis 1997, 176:1462-1467. 10.1086/514142, 9395355.